Akebia Therapeutics (AKBA) EBT Margin (2017 - 2026)
Akebia Therapeutics (AKBA) posted quarterly EBT Margin of 16.67% for Q1 2026, down 2733.0% year-over-year from 0.63% in Q1 2025, and up 14.48% quarter-over-quarter from 19.5% in Q4 2025.
Akebia Therapeutics (AKBA) EBT Margin (2017 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported EBT Margin for 10 consecutive years, with 16.67% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 2733.0% year-over-year to 16.67%; the TTM figure through Mar 2026 stood at 8.07% (up 1643.0% YoY), while the FY2025 annual figure was 1.58%, up 4176.0% from the prior year.
- EBT Margin grew to 16.67% in Q1 2026 per AKBA's latest filing, from 19.5% in the prior quarter.
- Across five years, EBT Margin topped out at 24.83% in Q2 2022 and bottomed at 81948.68% in Q1 2022.
- Historically, EBT Margin has averaged 4844.7% across 5 years, with a median of 19.66% in 2024.
- Annual changes were most pronounced in 2022 — EBT Margin sank 8181937 bps — and 2023, when it soared 8188150 bps.
- Akebia Therapeutics' EBT Margin stood at 7.39% in 2022, then jumped by 115 bps to 1.09% in 2023, then plunged by 4589 bps to 49.04% in 2024, then soared by 60 bps to 19.5% in 2025, then climbed by 14 bps to 16.67% in 2026.
- Business Quant data shows AKBA's EBT Margin at 16.67% in Q1 2026, 19.5% in Q4 2025, and 1.97% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | -17.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.99% |
| Mar 31, 2026 | -16.67% |
| Dec 31, 2025 | -19.50% |
| Sep 30, 2025 | 1.97% |
| Jun 30, 2025 | 0.40% |
| Mar 31, 2025 | 10.66% |
| Dec 31, 2024 | -49.04% |
| Sep 30, 2024 | -53.54% |
| Jun 30, 2024 | -19.66% |
| Mar 31, 2024 | -55.16% |
| Dec 31, 2023 | 1.09% |
| Sep 30, 2023 | -34.46% |
| Jun 30, 2023 | -19.82% |
| Mar 31, 2023 | -67.18% |
| Dec 31, 2022 | -7.39% |
| Sep 30, 2022 | -107.78% |
| Jun 30, 2022 | 24.83% |
| Mar 31, 2022 | -81,948.68% |
| Dec 31, 2021 | 44.81% |
| Sep 30, 2021 | -118.11% |